Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Weiss on Biomarkers in Head and Neck Cancer

Jared Weiss, MD
Published: Monday, Feb 13, 2017



Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses biomarkers in head and neck cancer.

Currently, one of the only available biomarkers for head and neck cancer is HPV. If the cancer is driven by HPV, it has more curative potential. But, this is not the optimal indicator for choosing treatment for patients with head and neck cancer, according to Weiss.

In regard to immunotherapy efficacy, Weiss says HPV isn’t a good biomarker. PD-L1 biomarkers are also problematic for immunotherapy, but some studies on interferon gamma signatures appear promising.
 


Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses biomarkers in head and neck cancer.

Currently, one of the only available biomarkers for head and neck cancer is HPV. If the cancer is driven by HPV, it has more curative potential. But, this is not the optimal indicator for choosing treatment for patients with head and neck cancer, according to Weiss.

In regard to immunotherapy efficacy, Weiss says HPV isn’t a good biomarker. PD-L1 biomarkers are also problematic for immunotherapy, but some studies on interferon gamma signatures appear promising.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x